All articles by Clinical Trials Arena Team

Clinical Trials Arena Team

Pipeline Moves: Advancement prospects plunge for Parkinson’s drug after trial termination

The Clinical Trials Arena team also reviews assets genetic disorders and metabolic disorders indications.

Pipeline Moves: Advancement prospects plunge for Bristol-Myers’ oncology drug after trial termination

The Clinical Trials Arena team also reviews assets in oncology, genetic disorders and metabolic disorders indications.

Pipeline Moves: Advancement prospects halt for refractory acute myeloid leukaemia therapy after trial suspension

The Clinical Trials Arena team also review assets in oncology and genetic disorders indications.

Pipeline Moves: Advancement prospects plunge for oesophageal adenocarcinoma therapy

The Clinical Trials Arena team also review assets in metabolic disorders, gastrointestinal and oncology indications.

Pipeline Moves: Advancement prospects drop for Novartis oncology drug after trial termination

The Clinical Trials Arena team also review assets in oncology and musculoskeletal disorder indications.

Pipeline Moves: Advancement prospects fall for Pfizer’s RSV therapy after trial termination

The Clinical Trials Arena team also review assets in oncology, ophthalmology, and genitourinary system indications.

Pipeline Moves: Advancement prospects fall for GM1 gene therapy after trial termination

The Clinical Trials Arena team also review assets in the central nervous system, oncology, metabolic and musculoskeletal disorders.

Pipeline Moves: Advancement prospects drop for Alzheimer’s drug after trial termination

The Clinical Trials Arena team also review assets in metabolic disorders, genitourinary system, central nervous system, and oncology indications.

Pipeline Moves: Novo Nordisk Phase III semaglutide completion bumps approval prospects

The Clinical Trials Arena team also investigate assets in ophthalmology, genitourinary system, immunology and oncology indications.

Pipeline Moves: Hengrui Medicine Phase III breast cancer termination lowers approval prospects

The Clinical Trials Arena team also review assets in the central nervous system, cardiology, renal, haematological and other oncology indications.